Sudheer Ummadi, MD
Nephrology · Allen Park, MINPI 1437118106
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.2% of the total across 445 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,453, 2.8 times the $869 reported in 2019. Among nephrology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 445 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Vifor Pharma, Inc.$1K
- Amgen$679
- Bard Peripheral Vascular, Inc.$595
- Fresenius USA Marketing, Inc.$512
- OPKO Pharmaceuticals, LLC$502
- plus $4K from 25 others
What the payments were for
- Speaking & faculty fees$4004%
- Travel & lodging$250%
- Food & beverage$8,60891%
- Education$4094%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 81 | $1,791 |
| Vifor Pharma, Inc. | 69 | $1,226 |
| Amgen(2 entities) | 36 | $679 |
| Bard Peripheral Vascular, Inc. | 10 | $595 |
| Fresenius USA Marketing, Inc. | 30 | $512 |
| OPKO Pharmaceuticals, LLC | 31 | $502 |
| Ardelyx, Inc. | 20 | $500 |
| Calliditas Therapeutics US Inc. | 20 | $442 |
| Travere Therapeutics, Inc. | 19 | $367 |
| Boehringer Ingelheim | 17 | $351 |
| Baxter Healthcare | 4 | $290 |
| Akebia Therapeutics Inc | 13 | $251 |
| Novartis | 12 | $247 |
| Otsuka America Pharmaceutical, Inc. | 8 | $188 |
| ANI Pharmaceuticals, Inc. | 7 | $154 |
| Aurinia Pharma U.S., Inc. | 10 | $152 |
| Mallinckrodt Hospital Products Inc. | 8 | $151 |
| GSK | 8 | $145 |
| Novo Nordisk | 5 | $133 |
| Daiichi Sankyo Inc. | 7 | $130 |
| Lilly USA, LLC | 6 | $118 |
| Boston Scientific | 5 | $117 |
| Apellis Pharmaceuticals, Inc. | 4 | $114 |
| Alnylam Pharmaceuticals Inc. | 3 | $67 |
| Cordis US CORP. | 3 | $60 |
| Bayer | 3 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $45 |
| Teleflex LLC | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$134
- LOKELMA$125
- TARPEYO$120
- XPHOZAH 30 MG$116
- Renal - PD$102
How this compares
$9,442 in reported general payments places this provider in the 90th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 105 | $118,273 |
| Cinacalcet Hcl | 54 | $51,348 |
| JardianceEmpagliflozin | 37 | $42,289 |
| LokelmaSodium Zirconium Cyclosilicate | 38 | $38,294 |
| VeltassaPatiromer Calcium Sorbitex | 27 | $36,852 |
| Sevelamer Carbonate | 62 | $24,328 |
| ProcritEpoetin Alfa | 13 | $16,003 |
| Calcitriol | 402 | $11,956 |
| JanuviaSitagliptin Phosphate | 12 | $11,781 |
| Calcium Acetate | 59 | $7,095 |
| Midodrine Hcl | 73 | $6,344 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 17 | $4,014 |
| Amlodipine Besylate | 453 | $3,820 |
| ProsolParenteral Amino Acid 20% No.1 | 29 | $3,456 |
| Losartan Potassium | 218 | $2,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,791 | $156,566143 claims |
| Boehringer IngelheimJardiance | $351 | $42,28937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 325 nephrology providers in Michigan.
Other nephrology in Allen Park
- Jeffrey GutmanAllen Park$6K
- Naushad PervezAllen Park$6K
- Alexander YevzlinAnn Arbor$1.1M
- Muwaffaq SalamehBay City$164K
- Laura MarianiAnn Arbor$150K
- Crystal Gardner-MartinLivonia$140K
- Katherine KwonSaint Joseph$111K
- Anatole BesarabDetroit$102K
- Richard CrossSaint Clair Shores$96K
- Kausik UmanathDetroit$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.